Acute Myocardial Infarction (AMI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Acute Myocardial Infarction (AMI) Market Outlook
Thelansis’s “Acute Myocardial
Infarction (AMI) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Acute
Myocardial Infarction (AMI) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Acute
Myocardial Infarction (AMI) Overview
Acute
myocardial infarction (AMI) is one of the most common diseases in developing
countries. It is commonly known as a heart attack, and it occurs when there is
a sudden blockage in blood flow in one or more of the coronary arteries,
cutting off blood supply to a part of the heart muscle and causing necrosis. If
the blockage is severe, the heart may stop beating. This is most commonly
caused by occlusion or blockage of a coronary artery caused by a vulnerable
atherosclerotic plaque rupture, an unstable collection of lipids and white
blood cells in the artery wall. Myocardial infarction usually begins in the
endocardium and spreads towards the epicardium. Acute myocardial infarction
symptoms include chest pain that may spread to the shoulder, arm, back, neck,
or jaw. This type of pain always begins in the center or left side of the chest
and lasts a few minutes. The onset of symptoms in acute myocardial infarction
is usually gradual, over several minutes, and rarely instantaneous.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment